227-OR: Tirzepatide Reduces HbA1c and Body Weight Significantly More Than Placebo Regardless of Insulin Sensitivity and Beta-Cell Function—Post Hoc Analysis from SURMOUNT-2
Diabetes（2024）
Neuss
Abstract
Treatment with tirzepatide (TZP) led to substantial improvements in body weight (BW) and glycemia compared to placebo in participants with obesity and type 2 diabetes (T2D) in SURMOUNT (SM)-2. In this analysis, we assessed whether baseline markers of pancreatic beta cell function and insulin sensitivity were associated with the magnitudes of BW and glycemic reductions. Post hoc analyses examined changes from baseline in BW and HbA1c in SM-2 at 72 weeks across HOMA2-B (computed with C-peptide) and HOMA2-IR (computed with insulin) quartiles (Q) from low (lower beta cell function/insulin resistance) (Q1) to high (Q4) as assessed by a mixed model for repeated measures using efficacy estimand. BW and HbA1c reductions were greater with TZP 10 mg and 15 mg than placebo within each HOMA2-B and HOMA2-IR baseline Q. More participants across all Qs achieved ≥15% BW reduction with TZP (36-63%) than placebo (up to 4%). More participants across all Qs reached HbA1c <5.7% with TZP (ranging from 42-71%) than placebo (up to 6%). TZP was more effective than placebo in reducing BW and HbA1c regardless of beta cell function and insulin resistance in participants with obesity and T2D. BW reductions with TZP trended greater with higher beta cell function, whereas HbA1c reduction trended greater with lower beta cell function. T. Heise: Research Support; ADOCIA, AstraZeneca, Biocon, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Genova, Novo Nordisk A/S. Consultant; Gan&Lee Pharmaceuticals. Speaker's Bureau; Eli Lilly and Company. Research Support; Altimmune Inc., Sanofi, Zealand Pharma A/S, BIOTON, Civica Foundation, Enyo Pharma, Gan&Lee Pharmaceuticals, Nanexa AB, SamChunDang Pharm. Co. H. Wang: None. C.J. Mast: Employee; Eli Lilly and Company. I. Benabbad: Employee; Eli Lilly and Company. C. Lee: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. B. Liao: Employee; Eli Lilly and Company.
MoreTranslated text
求助PDF
上传PDF
View via Publisher
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
- Pretraining has recently greatly promoted the development of natural language processing (NLP)
- We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
- We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
- The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
- Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper